The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Proteomic profiles of CRS following treatment with liso-cel and ide-cel
Abu-Sayeef Mirza, MD, MPH, Yale University, New Haven, CT, discusses the findings of a study that used multiplex proteomic profiling to evaluate and compare the impact of cytokine release syndrome (CRS) in patients with multiple myeloma treated with idecabtagene vicleucel (ide-cel) and in patients with diffuse large B-cell lymphoma (DLBCL) treated with lisocabtagene maraleucel (liso-cel). Overall, the study found that treatment with these two different constructs was associated with distinct cytokine profiles. A better understanding of the role of different cytokines playing a role in CRS might help uncover novel strategies to manage this complication. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
